REFERENCES
1. O’Hanlon R, Shaw ML. Baloxavir marboxil: the new influenza drug on the market.
Curr Opin Virol . 2019;35:14-18.
2. Mushtaq A. Baloxavir: game-changer or much ado about nothing? Lancet Respir Med. 2018;6:903-904.
3. Mullard A. FDA approves first new flu drug in 20 years. Nat Rev Drug Discov .
2018;17:853.
4. Roche Group. Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications. https://www.roche.com/media/releases/med-cor-2019-10-18.htm. Accessed May 11, 2020
5. Ministry of Health, Labour and Welfare in Japan. Monthly supply of antiviral drug against influenza (in Japanese). https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou01/jichitai.html. Accessed May 11, 2020
6. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir Marboxil for
Uncomplicated Influenza in Adults and Adolescents. N Engl J Med.2018;379:913-923.
7. Uehara T, Hayden FG, Kawaguchi K, et.al.Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza. J Infect Dis . 2020;221:346-355
8. National Institute of Infectious Disease in Japan. Detection of antiviral drug-resistant viruses in Japan during the 2018/2019 influenza season. https://www.niid.go.jp/niid/images/flu/resistance/20191128/dr18-19e20191126-1.pdf. Accessed May 11, 2020
9. Gubareva LV, Fry AM. Baloxavir and Treatment-Emergent Resistance: Public
Health Insights and Next Steps. J Infect Dis .2020;221:337-339
10. Omoto S, Speranzini V, Hashimoto T, et al. Characterization of influenza virus
variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.
Sci Rep . 2018;8:9633.
11. Kasamo S, Takeuchi M, Ikuno M et al. Real-world pharmacological treatment patterns of patients with young-onset Parkinson’s disease in Japan. J Neurol . 2019;266:1944-1952.
12. Suchard MA, Schuemie MJ, Krumholz HM, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.Lancet . 2019;394:1816-1826.
13. National Institute of Infectious Disease in Japan. Infectious Agents Surveillance Report. https://nesid4g.mhlw.go.jp/Byogentai/Pdf/data2j.pdf (in Japanese). Accessed May 11, 2020
14. ClinicalTrials.gov. Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications (CAPSTONE 2). https://clinicaltrials.gov/ct2/show/NCT02949011. Accessed May 11, 2020
15. Cromer D, van Hoek AJ, Jit M, Edmunds WJ, Fleming D, Miller E. The burden of
influenza in England by age and clinical risk group: a statistical analysis to
inform vaccine policy. J Infect. 2014;68(4):363-371.
16. Hardelid P, Verfuerden M, McMenamin J, Gilbert R. Risk factors for admission
to hospital with laboratory-confirmed influenza in young children: birth cohort
study. Eur Respir J. 2017;50. pii: 1700489.
17. Bassetti M, Castaldo N, Carnelutti A. Neuraminidase inhibitors as a strategy
for influenza treatment: pros, cons and future perspectives.